Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 1

Conditions

Breast Neoplasms 176Colorectal Neoplasms 153Rectal Neoplasms 122Stomach Neoplasms 112Pancreatic Neoplasms 60Neoplasm Metastasis 60Colonic Neoplasms 42Triple Negative Breast Neoplasms 34Neoplasms 29Esophageal Neoplasms 28Cholangiocarcinoma 17Biliary Tract Neoplasms 17Nasopharyngeal Carcinoma 16Gallbladder Neoplasms 16Carcinoma, Hepatocellular 16Adenocarcinoma 16Locally Advanced Rectal Cancer 15Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 10Esophageal Squamous Cell Carcinoma 10Brain Neoplasms 10Bile Duct Neoplasms 10Adenocarcinoma Of Esophagus 10Liver Neoplasms 9Gastrointestinal Neoplasms 9Breast Neoplasms, Male 9Neuroendocrine Tumors 7Colorectal Cancer Metastatic 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6

Interventions

Gemcitabine 9Carboplatin 8Paclitaxel 6Capecitabine 4Bevacizumab 4pembrolizumab 3Irinotecan 3Erlotinib Hydrochloride 3atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Filgrastim 2Cisplatin 2CP protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1entrectinib 1cobimetinib 1belinostat 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Unknown Primary × Capecitabine × Clear all
NCT01845337 2023-05-12

TOFFEE

University of Edinburgh

Phase 2 Completed
59 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms

NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193609 2013-11-11

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
48 enrolled 6 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00148135 2008-01-10

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

University of Michigan Rogel Cancer Center

Phase 2 Terminated
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡